MedTrace Logo

Interferon Alfa in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia

NCT00002869 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 800

Last updated 2013-12-19

No results posted yet for this study

Summary

RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Low doses of interferon alfa may be as effective as high doses.

PURPOSE: Randomized phase III trial to compare the effectiveness of low-dose or high-dose interferon alfa in treating patients who have newly diagnosed chronic myelogenous leukemia.

Conditions

Interventions

BIOLOGICAL

recombinant interferon alfa

DRUG

cytarabine

DRUG

hydroxyurea

Sponsors & Collaborators

Principal Investigators

  • Patricia Shepherd, MD · Edinburgh Cancer Centre at Western General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1995-04-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002869 on ClinicalTrials.gov